What if... We could harness the power of Flagship’s scientific platforms and create novel treatment options that benefit more patients, sooner?
Pioneering Medicines, an initiative of Flagship Pioneering, is building a world-class biopharmaceutical R&D capability focused on conceiving and developing life-changing treatments for patients by harnessing the power of Flagship's scientific platforms and applying those innovative approaches to serious diseases with unmet medical need. Unique to Pioneering Medicines’ approach is the opportunity to combine platforms to create truly novel and potentially transformative treatments.
About Flagship Pioneering:
Flagship Pioneering is a biotechnology company that invents and builds platform companies that change the world. We bring together the greatest scientific minds with entrepreneurial company builders and assemble the capital to allow them to take courageous leaps. Those big leaps in human health and sustainability exponentially accelerate scientific progress in areas ranging from cancer detection and treatment to nature-positive agriculture.
What sets Flagship apart is our ability to advance biotechnology by uniting life science innovation, company creation, and capital investment under one roof in a way that is largely without precedent. Our scientific founders, entrepreneurial leaders, and professional capital managers are each aligned around an institutionalized process that enables us to innovate and transform for the benefit of people and planet.
Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.
Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies.
Position Summary
We are seeking a Principal Scientist, DMPK (Biologics) for a contractor role to provide strategic and technical support across a diverse portfolio of large molecule drug discovery programs. The successful candidate will bring deep expertise in ADME/PK, bioanalysis, and immunogenicity risk assessment to support biologics discovery and optimization. This individual will play a key role in guiding candidate selection, preclinical study design, and data interpretation to drive decision-making and advance programs toward key milestones.
The ideal candidate is scientifically driven, proactive, detail-oriented, and thrives in a fast-paced, collaborative environment. Strong communication and project leadership skills are essential for success in this role.
Key Responsibilities
- Serve as the DMPK/BA representative on cross-functional discovery teams, driving project strategy and milestone achievement.
- Develop and drive DMPK, bioanalysis, and immunogenicity risk assessment strategies for biologics projects from discovery through early development.
- Design, oversee, and interpret ADME/PK, PK/PD, and biodistribution studies for antibodies, bispecifics, and other novel biologics.
- Coordinate with matrix discovery project team members for planning and executing DMPK-related activities.
- Collaborate with PK/PD modelers to establish exposure-response correlations and optimize study designs.
- Communicate scientific findings and recommendations to project teams, senior leadership, and external stakeholders.
- Provide oversight into DMPK, bioanalysis, and immunogenicity studies outsourced to external CROs.
- Help shape internal processes for DMPK functional excellence and operational efficiency.
Basic Qualifications
- Ph.D. in pharmaceutical sciences, biochemistry, or a related field with 5+ years of relevant industry experience; MS/BS with 10+ years will also be considered.
- Extensive experience with ADME/PK of biologics is required.
- Proven track record supporting biologics discovery and early development programs.
- Strong background in in vitro and in vivo ADME/PK study design, execution, and troubleshooting.
- Experience with CRO management and external study oversight is required.
- Strong interpersonal and communication skills, with the ability to effectively present complex data.
- Ability to manage multiple projects simultaneously in a dynamic, team-oriented environment.
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
#LI-LS1
Top Skills
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability.
Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions.
The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
